PDCD1 and prostate carcinoma: Serganova et al. [147] found that prostate-specific membrane antigen-specific CAR-T-cell therapy alone was ineffective in treating prostate cancer, while CAR-T-cell therapy combined with PDCD1 blockade resulted in better short-term outcomes in some patients [147].